Our Story
Commercialising academic research in regenerative medicine.
Tissue Regenix Group is a regenerative medicine company specialising in medical devices and allografts.
Spun out of the University of Leeds in 2006, we translate academic innovation into carefully engineered, clinically relevant tissue-based solutions.
Our proprietary dCELL® and BioRinse® technologies underpin a focused portfolio of xenograft and allograft products, manufactured in the UK and the US respectively, with quality, safety, and regulatory compliance at the centre of everything we do.
From receiving our first CE mark in 2010, to establishing US operations in 2012 and launching the first decellularised allograft, Dermapure®, in 2014, our progress has been guided by science and unmet clinical need. The acquisition of CellRight Technologies in 2017 expanded our allograft capabilities, while the CE marking of OrthoPure® XT in 2020 – and subsequent EU MDR certification in 2025 – marked a significant milestone in ligament reconstruction.
Today, Tissue Regenix Group continues to advance regenerative technologies that support the body’s natural healing processes, with a clear focus on evidence-led innovation and improved patient outcomes.